专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

121. 发明申请

WO1993006866A2 METHOD OF PROPHYLAXIS OR TREATMENT OF ANTIGEN PRESENTING CELL DRIVEN SKIN CONDITIONS USING INHIBITORS OF THE CD2/LFA-3 INTERACTION 审中-公开
标题翻译：使用CD2 / LFA-3相互作用的抑制剂预防或治疗抗原呈递细胞驱动的皮肤病症的方法
公开(公告)号：WO1993006866A2
公开(公告)日：1993-04-15
申请号：PCT/US1992008755
申请日：1992-10-06
申请人： BIOGEN, INC.
发明人： BIOGEN, INC. , WALLNER, Barbara, P. , COOPER, Kevin, D.
IPC分类号： A61K39/395
CPC分类号： C07K16/2824 , A61K38/00 , A61K2039/505 , C07K14/70507 , C07K14/70528 , C07K16/2806
摘要： Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
摘要翻译：使用CD2 / LFA-3相互作用抑制剂治疗特征在于包括人在内的哺乳动物的真皮和表皮中的T细胞激活和异常抗原呈递的皮肤病症的方法。这些病症包括牛皮癣，紫外线损伤，特应性皮炎，皮肤T细胞淋巴瘤如蕈样真菌病，过敏性和刺激性接触性皮炎，扁平苔藓，斑秃，坏疽性坏疽，白癜风，眼瘢痕性类天疱疮和荨麻疹。

122. 发明申请

WO1992016563A1 MONOCLONAL ANTIBODIES RECOGNIZING LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN-3 审中-公开
标题翻译：单克隆抗体识别淋巴功能相关抗原-3
公开(公告)号：WO1992016563A1
公开(公告)日：1992-10-01
申请号：PCT/US1992002044
申请日：1992-03-12
申请人： BIOGEN, INC. , SATO, Vicki, L. , CHISHOLM, Patricia, L. , WALLNER, Barbara, P.
发明人： BIOGEN, INC.
IPC分类号： C07K15/28
CPC分类号： C07K14/70528 , A61K38/00 , C07K16/2824
摘要： Monoclonal antibodies recognizing LFA-3 and capable of blocking adhesion of LFA-3-expressing cells to lymphocytes are described. Such antibodies are useful, e.g., in the treatment of disorders characterized by LFA-3-mediated adhesion of lymphocytes and in diagnostic methods and kits.

123. 发明申请

WO1992013952A1 IMPROVED INHIBITORS OF THROMBIN 审中-公开
标题翻译：改进的抑制剂
公开(公告)号：WO1992013952A1
公开(公告)日：1992-08-20
申请号：PCT/US1992000836
申请日：1992-02-03
申请人： BIOGEN, INC.
发明人： BIOGEN, INC. , MARAGANORE, John, M. , JABLONSKI, Jo-Ann, M. , BOURDON, Paul, R.
IPC分类号： C12N15/15
CPC分类号： C07K7/02 , A61K38/00 , C07K5/1016 , C07K14/815
摘要： This invention relates to novel biologically active molecules which bind to and inhibit thrombin. These molecules comprise a catalytic site directed moiety (CSDM) of formula (I), wherein X is hydrogen or is characterized by a backbone chain consisting of from 1 to 100 atoms; R1 is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted saturated ring structures; R2 is a bond or is characterized by a backbone chain consisting of from 1 to 5 atoms; R3 is a bond or is characterized by a backbone chain consisting of from 1 to 3 atoms; R4 is any amino acid; R5 is any L-amino acid which comprises a guanidinium- or amino-containing side chain group; R6 is a non-amide bond; and Y is characterized by a backbone chain consisting of from 1 to 9 atoms; or the formula (II), wherein R1' is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted ring structures; R4' is any amino acid comprising a side chain group characterized by the capacity to accept a hydrogen bond at a pH of between about 5.5 and 9.5; and X, R2, R3, R5, R6 and Y are defined as above. Preferred thrombin inhibitors are further characterized by an anion binding exosite associating domain (ABEAM) and a linker portion of between 18 ANGSTROM and 42 ANGSTROM in length which connects the Y to the ABEAM. This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.
摘要翻译：本发明涉及结合并抑制凝血酶的新型生物活性分子。这些分子包含式（I）的催化位点定向部分（CSDM），其中X是氢或其特征在于由1至100个原子组成的主链; R1选自未取代的，单取代的，二取代的和三取代的饱和环结构; R2是键或其特征在于由1至5个原子组成的主链; R3是键或其特征在于由1至3个原子组成的主链; R4是任何氨基酸; R5是包含含胍基或氨基的侧链基团的任何L-氨基酸; R6是非酰胺键; 并且Y的特征在于由1至9个原子组成的主链; 或式（II），其中R 1'选自未取代的，单取代的，二取代的和三取代的环结构; R4'是包含侧链基团的任何氨基酸，其特征在于在约5.5和9.5之间的pH下接受氢键的能力; X，R2，R3，R5，R6和Y如上所定义。优选的凝血酶抑制剂的进一步特征在于阴离子结合外部位点缔合结构域（ABEAM）和连接Y与ABEAM的长度为18 ANGSTROM和42 ANGSTROM之间的接头部分。本发明还涉及使用这些分子用于治疗，预防和诊断目的的组合物，组合和方法。

124. 发明申请

WO1992012728A1 REPRESSORS OF THE TRANS-ACTIVATING FUNCTION OF PAPILLOMAVIRUS E2 PROTEINS 审中-公开
标题翻译： PAPIROMAVIRUS E2蛋白转移功能的代谢物
公开(公告)号：WO1992012728A1
公开(公告)日：1992-08-06
申请号：PCT/US1992000652
申请日：1992-01-28
申请人： BIOGEN, INC. , NEW ENGLAND MEDICAL CENTER HORSPITALS, INC. , ANDROPHY, Elliot, J. , BARSOUM, James, G.
发明人： BIOGEN, INC. , NEW ENGLAND MEDICAL CENTER HORSPITALS, INC.
IPC分类号： C12N15/37
CPC分类号： C07K14/005 , A61K38/00 , C07K2319/00 , C07K2319/61 , C07K2319/80 , C12N2710/20022 , C12N2740/16322 , Y10S530/826
摘要： This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. Native full-length E2 trans-activation protein activates transcription of papillomavirus only through binding to DNA, and it binds to DNA only in the form of a pre-formed homodimer -- a pair of identical polypeptide subunits held together by non-covalent interactions. The E2 trans-activation repressors of this invention are proteins, polypeptides or other molecules that dimerize with full-length native E2 polypeptides to form inactive heterodimers, thus interfering with the formation of active homodimers comprising full-length native E2 polypeptides, thereby repressing papillomavirus transcription and replication. The E2 trans-activation repressors of this invention are advantageously used in the treatment of papillomavirus infections and their associated diseases.

125. 发明申请

WO1991001328A1 HIRUDIN PEPTIDE DERIVATIVES 审中-公开
标题翻译：呼吸肽衍生物
公开(公告)号：WO1991001328A1
公开(公告)日：1991-02-07
申请号：PCT/US1990004109
申请日：1990-07-20
申请人： BIOGEN, INC.
发明人： BIOGEN, INC. , MARAGANORE, John, M.
IPC分类号： C07K07/08
CPC分类号： C07K14/815 , A61K38/00 , A61K51/08 , A61K51/088 , A61K2123/00 , A61L33/0047 , A61L33/128
摘要： This invention relates to novel, biologically active peptide derivatives which inhibit the fibrinolytic, but not the amidolytic activity of thrombin. The peptide derivatives, which display partial homology to the carboxy terminal portion of hirudin, are characterized by a modified tyrosine or cysteine residue at a predetermined site in the molecule. This invention also relates to compositions and methods employing such peptide derivatives for therapeutic, prophylactic or diagnostic purposes. This invention also relates to platelet and endothelial cell inhibitory compositions and methods characterized by the above-described peptide derivatives or similar peptide derivatives which do not contain a modified cysteine or tyrosine residue at a corresponding locus in the molecule. These methods and compositions are advantageously useful for decreasing or preventing platelet aggregation and platelet activation in a patient or in extracorporeal blood, especially in patients who have a history of heparin-induced thrombocytopenia.
摘要翻译：本发明涉及抑制纤维蛋白溶解而不是凝血酶的酰胺分解活性的新型生物活性肽衍生物。与水蛭素的羧基末端部分显示部分同源性的肽衍生物的特征在于分子中预定位点处的修饰的酪氨酸或半胱氨酸残基。本发明还涉及使用这些肽衍生物用于治疗，预防或诊断目的的组合物和方法。本发明还涉及血小板和内皮细胞抑制组合物和方法，其特征在于在分子中相应基因座处不含修饰的半胱氨酸或酪氨酸残基的上述肽衍生物或相似的肽衍生物。这些方法和组合物有利于减少或预防患者或体外血液中的血小板聚集和血小板活化，特别是在具有肝素诱导的血小板减少症史的患者中。

126. 发明申请

WO1990006128A1 METHODS AND COMPOSITIONS FOR INHIBITING PLATELET AGGREGATION 审中-公开
标题翻译：抑制血小板聚集的方法和组合物
公开(公告)号：WO1990006128A1
公开(公告)日：1990-06-14
申请号：PCT/US1989000849
申请日：1989-03-02
申请人： BIOGEN, INC. , TRUSTEES OF BOSTON UNIVERSITY
发明人： BIOGEN, INC. , TRUSTEES OF BOSTON UNIVERSITY , MARAGANORE, John, M. , JAKUBOWSKI, Joseph, A.
IPC分类号： A61K37/02
CPC分类号： C07K14/815 , A61K38/00
摘要： This invention relates to anticoagulant and platelet inhibitory compositions, combinations and methods characterized by biologically active peptides which display the anticoagulant and platelet inhibitory activities of hirudin, or analogs thereof, for therapeutic and prophylactic purposes. The methods, compositions and combinations of this invention and advantageously useful for decreasing or preventing platelet aggregation and platelet activation in a patient or a biological sample. These methods, compositions and combinations are particularly useful in patients for whom standard heparin therapy is contraindicated due to a history of heparin-induced thrombocytopenia or an antithrombin III deficiency. This invention also relates to methods, compositions and combinations for treating extracorporeal blood and for increasing platelet storage life.

127. 发明申请

WO1990003391A1 HIRUDIN PEPTIDES 审中-公开
公开(公告)号：WO1990003391A1
公开(公告)日：1990-04-05
申请号：PCT/US1989000848
申请日：1989-04-24
申请人： BIOGEN, INC.
发明人： BIOGEN, INC. , MARAGANORE, John, M.
IPC分类号： C07K07/06
CPC分类号： C07K14/815 , A61K38/00
摘要： This invention relates to novel, biologically active peptides which display the anticoagulant activity of hirudin. More specifically, it relates to peptides which are homologous to at least a portion of the carboxy terminal 26 amino acids of hirudin. Such peptides may also be characterized by a modified tyrosine residue. This invention further relates to covalent and peptidomimetic analogs of these peptides which display anticoagulant activity. This invention also relates to compositions, combinations and methods using such peptides or analogs for therapeutic, prophylactic or diagnostic purposes. And this invention relates to novel methods for sulfating tyrosine residues contained within the peptide or polypeptide.
摘要翻译：本发明涉及显示水蛭素抗凝活性的新型生物活性肽。更具体地，涉及与水蛭素的至少一部分羧基末端26个氨基酸同源的肽。这样的肽也可以由修饰的酪氨酸残基表征。本发明还涉及显示抗凝血活性的这些肽的共价和拟肽类似物。本发明还涉及使用这些肽或类似物用于治疗，预防或诊断目的的组合物，组合和方法。本发明涉及用于硫酸化包含在肽或多肽内的酪氨酸残基的新方法。

128. 发明申请

WO1989011860A1 COMBINATIONS OF SOLUBLE T4 PROTEINS AND ANTI-RETROVIRAL AGENTS AND METHODS FOR TREATING OR PREVENTING AIDS, ARC AND HIV INFECTION 审中-公开
标题翻译：可溶性T4蛋白和抗逆转录病毒药物的组合以及治疗或预防艾滋病，感染和艾滋病毒感染的方法
公开(公告)号：WO1989011860A1
公开(公告)日：1989-12-14
申请号：PCT/US1989002453
申请日：1989-06-08
申请人： BIOGEN, INC. , THE GENERAL HOSPITAL CORPORATION
发明人： BIOGEN, INC. , THE GENERAL HOSPITAL CORPORATION , FISHER, Richard, A. , SCHOOLEY, Robert, T. , HIRSCH, Martin, S. , JOHNSON, Victoria, A. , WALKER, Bruce, D.
IPC分类号： A61K37/02
CPC分类号： A61K38/1774 , A61K31/437 , A61K31/445 , A61K31/7072 , A61K45/06 , A61K2300/00
摘要： This invention relates to combinations and methods useful for the treatment or prevention of acquired immunodeficiency syndrome, AIDS related complex, and HIV infection. More particularly, this invention relates to pharmaceutically effective combinations of a soluble T4 protein and an anti-retroviral agent for treating or preventing AIDS, ARC and HIV infection. According to this invention, a soluble T4 protein is used in a pharmaceutically effective combination with an anti-retroviral agent, such as AZT or a glucosidase inhibitor, the dosage of the soluble T4 protein and the dosage of the anti-retroviral agent each being less than that required for a desired therapeutic or prophylactic effect when either compound is administered as a monotherapy.
摘要翻译：本发明涉及可用于治疗或预防获得性免疫缺陷综合征，AIDS相关复合物和HIV感染的组合和方法。更具体地，本发明涉及用于治疗或预防AIDS，ARC和HIV感染的可溶性T4蛋白和抗逆转录病毒剂的药学上有效的组合。根据本发明，可溶性T4蛋白与抗逆转录病毒药物如AZT或葡糖苷酶抑制剂的药学上有效的组合使用，可溶性T4蛋白的用量和抗逆转录病毒剂的剂量各自不多当将任一化合物作为单一疗法施用时，所需的治疗或预防效果所需的量。

129. 发明申请

WO1989001946A1 BIOLOGICAL MATERIALS, PROCESSES FOR PRODUCING BIOLOGICAL MATERIALS AND FOR USING SUCH MATERIALS IN THERAPY 审中-公开
标题翻译：生物材料，用于生产生物材料和使用这些材料的治疗方法
公开(公告)号：WO1989001946A1
公开(公告)日：1989-03-09
申请号：PCT/US1988002819
申请日：1988-08-17
申请人： BIOGEN, INC. , DAYER, Jean-Michel , SECKINGER, Philippe, Lucien , MAZZEI, Gonzalo, Jose , SHAW, Alan, Reed
发明人： BIOGEN, INC.
IPC分类号： C07K15/00
CPC分类号： C07K14/4703 , A61K38/00
摘要： This invention relates to interleukin 1 inhibitors (IL-1 INHs) that selectively inhibit interleukin 1 activity. The invention also relates to processes for purifying such IL-1 INHs from urine and for producing such IL-1 INHs by hosts transformed with recombinant DNA molecules comprising DNA sequences encoding the inhibitors, and to methods of treatment and compositions characterized by such IL-1 INHs. These methods and agents are useful in immunosuppressive and anti-inflammatory applications and therapies.

130. 发明申请

WO2018085521A2 NOVEL DOSAGE REGIMEN 审中-公开
标题翻译：新的剂量方案
公开(公告)号：WO2018085521A2
公开(公告)日：2018-05-11
申请号：PCT/US2017/059691
申请日：2017-11-02
申请人： BIOGEN INC. , BIOGEN MA INC.
发明人： MORISSET, Valerie , NAIK, Himanshu , DUNBAR, Joi , VERSAVEL, Mark
摘要： The present invention is directed to a novel method of treating a disease or condition mediated by modulation of Nav1.7 and other voltage-gated sodium channel subtypes, such as pain, in particular neuropathic pain, most particularly trigeminal neuralgia.
摘要翻译：本发明涉及治疗由Nav1.7和其他电压门控钠通道亚型如疼痛，特别是神经性疼痛，尤其是神经性疼痛的调节介导的疾病或病症的最新方法三叉神经痛。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式